Moleculin to Participate in the Virtual Investor Lunch Break Series
Moleculin to Participate in the Virtual Investor Lunch Break Series
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET
2024年6月12日星期三，莫勒克林生物技术公司的董事长兼首席执行官沃尔特•克莱普将在现场直播中发言。th东部时间下午12:00
HOUSTON, June 5, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Wednesday, June 12, 2024 at 12:00 PM ET.
2024年6月5日，休斯顿——莫勒克林生物技术公司（纳斯达克股票代码：MBRX）是一家临床阶段的药品公司，拥有面向难治性肿瘤和病毒的广泛药物组合，并于今天宣布将在《虚拟投资者午餐休息：莫勒克林机会》活动上发言。莫勒克林机遇：虚拟投资者午餐休息该活动将于2024年6月12日星期三上午12:00（东部时间）举行。
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Klemp will answer as many questions as possible in the time allowed.
作为活动的一部分，莫勒克林公司的董事长和首席执行官沃尔特•克莱普将提供公司概述和业务前景。除了准备好的发言外，有兴趣的人可以在活动期间在线提交问题。克莱普先生将在允许的时间内回答尽可能多的问题。
A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
机器人演示的网络直播视频将在公司网站（aimimmuno.com）的“活动”页面上提供。演示的网络直播视频将在现场演示后两小时提供，并可访问90天。本次活动的直播将在公司网站的活动页面下提供。的信息，请访问aimimmuno.com并与公司联系。所有板块投资者，详见公司网站（moleculin.com）。现场活动结束两小时后，将提供网络直播回放，并可供观看90天。
About Moleculin Biotech, Inc.
关于莫勒克林生物技术公司Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data related to its active clinical trials are subject to change.
莫勒克林生物技术公司是一家临床阶段的药品公司，拥有一个不断增长的药物组合，包括第二阶段临床试验计划，用于难治性肿瘤和病毒。公司的领先项目安纳霉素是一种下一代蒽环类药物，旨在避免多药耐药机制，并消除目前处方蒽环类药物常见的心脏毒性。安纳霉素目前正在开发用于治疗复发或难治性急性髓细胞白血病（AML）和软组织肉瘤（STS）肺转移病例。与正在进行的临床试验相关的所有中期和初步数据都可能会发生变化。
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.
此外，公司正在开发WP1066——一种能够抑制p-STAT3和其他致癌转录因子并同时刺激自然免疫反应的免疫/转录调节剂，用于治疗脑肿瘤、胰腺癌和其他癌症。莫勒克林还致力于开发一系列抗代谢物，包括WP1122，用于潜在的病毒治疗，以及某些癌症适应症。
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
有关该公司的更多信息，请访问其官网www.moleculin.com，并关注推特, LinkedIn和页面。Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
投资者联系人：
JTC团队有限责任公司
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-lunch-break-series-302163997.html
查看下载多媒体原始内容：资讯来源：Moleculin将参加虚拟投资者午餐会系列活动。
SOURCE Moleculin Biotech, Inc.
资讯来源：Moleculin生物科技公司。